Skip to content

Zinc dosing trial for the treatment of acute diarrhea in under five children in a South Asian Setting

Establishing the optimal dose of therapeutic zinc supplementation for the treatment of acute diarrhea in under five children - a dose response trial in a South Asian and a Sub-Saharan African setting

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/01/007628
Enrollment
4500
Registered
2017-01-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Children with acute diarrhea

Interventions

Intervention1: zinc 10 mg dose: Administration: oral
Duration: 14 days, Dose per day: once daily Intervention2: zinc 5 mg dose: Administration: oral
Duration: 14 days, Dose per day: once daily Control Intervention1: zinc 20 mg dose (standard treatment): Administration: oral
Duration: 14 days, Dose per day: once daily

Sponsors

Center For Public Health Kinetics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Males and females 6 to 59 completed months of age b. Acute diarrhoea of less than 72 hours at the time of screening c. Dysentery, defined as visible blood in the stool, of less than 72 hours at the time of screening d. Likely to stay within the study area for the next 2 months e. Written informed consent from caretaker

Exclusion criteria

Exclusion criteria: a.Presence of severe acute malnutrition (WHZ b.Presence of severe dehydration that cannot be corrected in 4 to 6 hours c.Signs of severe pneumonia (WHO definition of pneumonia with danger signs), sepsis, RDT-confirmed malaria or other severe illness d. Previously or currently enrolled in the study e. child currently enrolled in another study f. Other child in the family is currently enrolled in the study in the same household g. Not intending to remain in study area for the duration of the study h. Parents refuse participation in the study.

Design outcomes

Primary

MeasureTime frame
Diarrhoea duration -Diarrhoea continuing beyond five days -Total number of loose or watery stools after enrollment -Proportion of children vomiting within 30 minutes of administration of zinc tablet Timepoint: From enrollment until the recovery of the diarrheal episode (2 diarrheal free days)

Secondary

MeasureTime frame
-Serious adverse events (life-threatening or requiring hospitalization) -Diarrhoea continuing beyond three days -Acceptability of the different doses of zinc -Mean serum plasma zinc levels. -Cause-specific illness prevalence at 30 and 60 days post-acute illness -Treatment adherence /duration Timepoint: -From enrollment till 60 days follow up -From randomization till resolution of diarrhoea -From randomization till 14 days of supplementation period - At Days 1,3, 7, 15, 21 and 30 - Day 30 and Day 60 -From randomization till 14 days of supplementation period

Countries

India, United Republic of Tanzania

Contacts

Public ContactDr P K Gupta

Center For Public Health Kinetics

ssazawal@jhu.edu91-11-41724901

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026